ArticleMedicine, health care, and philosophy2017
Ethical issues in nanomedicine: Tempest in a teapot?
Article in Medicine, health care, and philosophy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Ethical Implications of Tissue Engineering for Regenerative Purposes: A Systematic Review.Tissue engineering. Part B, Reviews · 2023Pooled it
- Intranasal Delivery of Solid Lipid Nanoparticles Loaded with Carmustine and Temozolomide for Glioblastoma Treatment in Mice.AAPS PharmSciTech · 2026Article
- Nano-antioxidants for neurodegenerative disorders: a scoping review.Discover nano · 2025Review
- Nano Revolution: "Tiny tech, big impact: How nanotechnology is driving SDGs progress".Heliyon · 2024Review
- Translational Challenges and Prospective Solutions in the Implementation of Biomimetic Delivery Systems.Pharmaceutics · 2023Review
- Ethical and legal challenges in nanomedical innovations: a scoping review.Frontiers in genetics · 2023Article
- An Elucidative Review to Analytically Sieve the Viability of Nanomedicine Market.Journal of pharmaceutical innovation · 2022Review
- Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.Nanomedicine (London, England) · 2019Review
- Emerging technologies and the voice of reason.Medicine, health care, and philosophy · 2017Article
- Important ethical issues for nanomedicine.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanomedicine offers remarkable options for new therapeutic avenues. As methods in nanomedicine advance, ethical questions conjunctly arise. Nanomedicine is an exceptional niche in several aspects as it reflects risks and uncertainties not encountered in other areas of medical research or practice. Nanomedicine partially overlaps, partially interlocks and partially exceeds other medical disciplines. Some interpreters agree that advances in nanotechnology may pose varied ethical challenges, whilst others argue that these challenges are not new and that nanotechnology basically echoes recurrent bioethical dilemmas. The purpose of this article is to discuss some of the ethical issues related to nanomedicine and to reflect on the question whether nanomedicine generates ethical challenges of new and unique nature. Such a determination should have implications on regulatory processes and professional conducts and protocols in the future.
Indexed as
Identifiers
27522374What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.